Company intelligence / Profile preview

Meiji Seika Pharma

Tokyo, Tokyo-to, Japanmeiji.com ↗

Ownership: Private
Development stage: Other

Overview

Meiji Seika Pharma is a leading Japanese pharmaceutical company with a strong focus on infectious diseases—especially antibacterial drugs—holding over 50% market share in injectable penicillin-based antibacterials in Japan. The company also markets treatments for CNS disorders and allergies and is active in the development of generic anticancer drugs and biosimilars. It has an established presence in both branded and generic pharmaceuticals as well as contract manufacturing services.

Therapeutic areas: PsychiatryImmunologyOncologyInfectious Diseases
Modalities: Small moleculeBiologicVaccine
Industry: Biotech

Partnerships

Academic collaborations with Kyoto UniversityKumamoto UniversityJuntendo UniversityKitasato Universitypartnerships for biosimilar/generic drug development

Beyond the preview

Go deeper on Meiji Seika Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meiji Seika Pharma.

Explore the full profile